The Koschmann lab is studying the molecular mechanisms by which mutations promote tumor formation and genetic instability in pediatric high-grade glioma (HGG), including anaplastic astrocytoma (AA), glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). Their work is currently focused on how mutations in pediatric and young adult HGG might affect response to novel DNA-damaging and immune-based therapies.
Additionally, along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, Dr. Koschmann developed and co-facilitates the University of Michigan Brain Tumor Precision Medicine conference. This multi-disciplinary panel incorporates molecular results obtained from the brain tumors of children and young adults into the selection of targeted therapies with the highest likelihood of crossing the blood brain barrier. The Koschmann lab is working to develop new algorithms for the use of molecularly targeted therapy for children and young adults with brain tumors, and the U-M Brain Tumor Program already treated dozens of patients with agents selected from this translational program.